ImmunoScape is a biotechnology company developing combination cancer therapies, specifically utilizing a novel seed-and-boost approach designed to deliver anti-tumor efficacy at a lower cost. The company serves the biopharmaceutical and oncology healthcare sectors.
Subscribe to see ImmunoScape’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ImmunoScape is a biotechnology company headquartered in Singapore. Xcout tracks 13 named people at ImmunoScape, including Romi Chandiramani (CHIEF FINANCIAL OFFICER).
7 more named people on record for ImmunoScape, with roles, board committees and tenure — see the full roster →
A few of ImmunoScape's closest competitors — see the full list of competitors and alternatives →
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
BioEclipse Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in California. The company is focused on researching and developing a novel generation of targeted immunotherapies and treatments for oncology.
Irazu Oncology, LLC is a biotechnology company that develops cancer immunotherapies utilizing bacterial outer membrane vesicles. The company creates off-the-shelf treatments designed to activate anti-tumor immune responses through a scalable manufacturing process, aiming to provide more accessible and affordable therapeutic options for cancer patients.
Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.
ImmunoPhotonics, Inc. is a privately owned clinical-stage biopharmaceutical and pharmaceutical manufacturing company located in St. Louis, Missouri, specializing in interventional immuno-oncology.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.